Hoth Therapeutics, Inc.’s BioLexa in AD: So Far, So Safe

No serious adverse events and no drug-related treatment-emergent adverse events were observed in Cohort 1.

Hoth Therapeutics, Inc.’s BioLexa was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed, according to the safety results in Cohort 1 of its first in human clinical trial of the BioLexa platform to treat atopic dermatitis. 

BioLexa has been administered twice per day for 14 days to the first ten subjects within Cohort 1.

"Today's announcement represents a significant milestone for Hoth," states Robb Knie, CEO of Hoth Therapeutics, in a news release.  "We are very pleased by the Cohort 1 results and are proceeding as planned with submission and enrollment for Cohort 2 with atopic dermatitis patients later this year."